Trending...
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- Salena Kelley Returns as Ms. Salena With New Holiday Music Now Streaming Everywhere
DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Pemetrexed Lyo. Injection is therapeutically equivalent to Eli Lilly and Company's ALIMTA® and approved to treat Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity.1 Accord's product is offered in vials of 100mg, 500mg, and 1000mg strengths and is currently available to ship.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
- LTL Claims Ratio Index – Update 3Q25
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Billion Strong Foundation Upgrades 3X Skills + Career Finder and New AI Impact Engine
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- Greensboro's Leading Custom Sign Company Expands Services to Help Local Businesses Strengthen Their Brand Presence
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
- Spark Announces 2025 Design Award Winners
- Whitney Hill Declares Run for Raleigh City Council District A
- NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
- Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
- Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
- UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- Carolina Cabinet Pros Earns Repeat Honor with Prestigious 2025 Angi's Super Service Award
- KIKO NATION TOKEN (Official Release)
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology